Changes this week
Changes detected in the 7 days to Nov 20, 2026
- Minor: Mirivadelgat in PH-ILD (Windward) Trial sites expanded: 11 → 15 locations
- Minor: VTX2735 in Recurrent Pericarditis Trial sites expanded: 19 → 28 locations
- Minor: Symbiotic-GU-06 · PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer Trial sites expanded: 184 → 198 locations
- Minor: Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC Trial sites expanded: 37 → 66 locations
- Minor: Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH) Trial sites expanded: 30 → 36 locations
- Minor: [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) · Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors Trial sites expanded: 6 → 9 locations
- Minor: Symbiotic-GI-13 · PF-08634404 as a Single Treatment and Combination Treatment · a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body Trial sites expanded: 58 → 81 locations
- Minor: Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers Trial sites expanded: 104 → 108 locations
- Minor: MAR001 · Elevated Triglycerides and Remnant Cholesterol Trial sites expanded: 55 → 62 locations
- Minor: Taking an Additional Dose of the Medicine Rimegepant · Migraine Trial sites expanded: 24 → 38 locations
- Minor: Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy · Transformed Small Cell Lung Cancer Trial sites expanded: 61 → 75 locations
- Minor: Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 · Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) Trial sites expanded: 13 → 17 locations
- Minor: AIR-001 · Alpha-1 Antitrypsin Deficiency (AATD) Trial sites expanded: 12 → 15 locations
- Minor: UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study · Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance Trial sites expanded: 52 → 85 locations
- Minor: OPTION-EMEA Clinical Trial Trial sites expanded: 11 → 14 locations
- Minor: Global Paradise System US Post Approval Study Trial sites expanded: 46 → 49 locations
- Minor: Voice-based Outcome Identification and Clinical Evaluation in Heart Failure Trial sites expanded: 0 → 4 locations
- Minor: BIO|MASTER.CorSky Family Post-market Study for the CorSky Family of ICDs Trial sites expanded: 7 → 15 locations
- Minor: Elite AF IDE Trial (Elite AF) Trial sites expanded: 0 → 5 locations
- Minor: EVERO Drug-coated Balloon (DCB) Randomized Trial Trial sites expanded: 15 → 19 locations
- Minor: Immunotherapy After Surgery · No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial Trial sites expanded: 284 → 287 locations
- Minor: Knee Cartilage Repair Registry Trial sites expanded: 6 → 9 locations
- Minor: Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial Trial sites expanded: 148 → 171 locations
- Minor: Different Treatment Lengths for Venetoclax · Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Trial sites expanded: 69 → 83 locations
- Minor: Belzutifan (MK-6482) Versus Everolimus · Advanced Renal Cell Carcinoma (MK-6482-005) Study completion pushed from Sep 17, 2026 to Nov 11, 2026
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates